Pharmacogenetic analysis of human steroid 5α reductase type II: comparison of finasteride and dutasteride

    Nick M. Makridakis, Juergen K. V. Reichardt
    Image of study
    TLDR Dutasteride is more efficient than finasteride, but individual results vary.
    This study analyzed the pharmacogenetics of finasteride and dutasteride, two drugs used to treat prostatic diseases. The study found that both drugs are slow, time-dependent inhibitors of steroid 5α-reductase type II, with dutasteride being a more efficient inhibitor than finasteride for most enzyme variants. However, there is significant pharmacogenetic variation for both drugs, which should be taken into account when designing treatment protocols. The study suggests that pharmacogenetic analysis could be used to determine which drug would be most effective for individual patients.
    View this study on →

    Cited in this study